Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy.
The Mucopolysaccharidosis type II (MPS II) (Hunter Syndrome) pipeline market research report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report also provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and features dormant and discontinued projects.
MPS II Pipeline Products Market by Targets
The key target in the MPS II pipeline products market is Iduronate 2 Sulfatase.
MPS II Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the MPS II pipeline products market are Iduronate 2 Sulfatase Activator, and Iduronate 2 Sulfatase Replacement. Iduronate 2 Sulfatase Activator is the leading mechanism of action in the MPS II pipeline products market.
MPS II Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the MPS II pipeline products market, download a free report sample
MPS II Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the MPS II pipeline products market are intravenous, parenteral, subcutaneous, intracerebral, intracisternal, and intrathecal. Most of the products are administered through the intravenous route.
MPS II Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the MPS II pipeline products market, download a free report sample
MPS II Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the MPS II pipeline products market are gene therapy, recombinant enzyme, gene-modified cell therapy, biologic, cell therapy, fusion protein, oligonucleotide, and polysaccharide. Gene therapy and recombinant enzyme are the leading molecule types in the MPS II pipeline products market.
MPS II Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the MPS II pipeline products market, download a free report sample
MPS II Pipeline Products Market - Competitive Landscape
Some of the leading companies in the MPS II pipeline products market are GC Biopharma Corp, AVROBIO Inc, Homology Medicines Inc, JCR Pharmaceuticals Co Ltd, AngioChem Inc, Apteeus SAS, Bioasis Technologies Inc, Biorchestra Co Ltd, Capsida Biotherapeutics Inc, and Denali Therapeutics Inc. GC Biopharma Corp is the leading company in the MPS II pipeline products market.
MPS II Pipeline Products Market Analysis by Companies
To know more about the leading players in the MPS II pipeline products market, download a free report sample
MPS II Pipeline Products Market Report Overview
| Key Target | Iduronate 2 Sulfatase |
| Key Mechanisms of Action | Iduronate 2 Sulfatase Activator, and Iduronate 2 Sulfatase Replacement |
| Key Routes of Administration | Intravenous, Parenteral, Subcutaneous, Intracerebral, Intracisternal, and Intrathecal |
| Key Molecule Types | Gene Therapy, Recombinant Enzyme, Gene-Modified Cell Therapy, Biologic, Cell Therapy, Fusion Protein, Oligonucleotide, and Polysaccharide |
| Leading Companies | GC Biopharma Corp, AVROBIO Inc, Homology Medicines Inc, JCR Pharmaceuticals Co Ltd, AngioChem Inc, Apteeus SAS, Bioasis Technologies Inc, Biorchestra Co Ltd, Capsida Biotherapeutics Inc, and Denali Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Apteeus SAS
AVROBIO Inc
Bioasis Technologies Inc
Biorchestra Co Ltd
Capsida Biotherapeutics Inc
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
GC Biopharma Corp
Generium
Homology Medicines Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
ReqMed Co Ltd
Sigilon Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the MPS II pipeline products market?
The key target in the MPS II pipeline products market is Iduronate 2 Sulfatase.
-
What are the key mechanisms of action in the MPS II pipeline products market?
The key mechanisms of action in the MPS II pipeline products market are Iduronate 2 Sulfatase Activator, and Iduronate 2 Sulfatase Replacement.
-
What are the key routes of administration in the MPS II pipeline products market?
The key routes of administration in the MPS II pipeline products market are intravenous, parenteral, subcutaneous, intracerebral, intracisternal, and intrathecal.
-
What are the key molecule types in the MPS II pipeline products market?
The key molecule types in the MPS II pipeline products market are gene therapy, recombinant enzyme, gene-modified cell therapy, biologic, cell therapy, fusion protein, oligonucleotide, and polysaccharide.
-
Which are the leading companies in the MPS II pipeline products market?
Some of the leading companies in the MPS II pipeline products market are GC Biopharma Corp, AVROBIO Inc, Homology Medicines Inc, JCR Pharmaceuticals Co Ltd, AngioChem Inc, Apteeus SAS, Bioasis Technologies Inc, Biorchestra Co Ltd, Capsida Biotherapeutics Inc, and Denali Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports